

GLAXOSMITHKLINE PLC  
Form 6-K  
February 20, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 20 February 2018

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')  
 Shares sold to meet tax liabilities

Following the vesting of the pre-tax awards granted in 2015 under the GlaxoSmithKline Deferred Annual Bonus Plan ('DABP') on 15 February 2018 and as notified on 16 February 2018, the notifications that follow reflect change in the interests of the Person Discharging Managerial Responsibilities ('PDMRs') in American Depositary Shares ('ADS') of the Company arising from the sale of ADSs to meet tax liabilities.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

GlaxoSmithKline plc  
 American Depositary Shares ('ADSs')  
 ISIN: US37733W1053

a) Description of the financial instrument

b) Nature of the transaction

The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c) Price(s) and volume(s)

Price(s)	Volume(s)
\$37.4803	3,480 (Deferred)
\$37.4803	2,520 (Matching)

d) Aggregated information  
 Aggregated volume Price

6,000  
 \$37.4803

e) Date of the transaction

2018-02-16

f) Place of the transaction

New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 20, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc